Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

United States - English - NLM (National Library of Medicine)

ethex corporation - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. morphine sulfate extended-release 100 mg and 200 mg tablet strengths are high dose, controlled-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release tablets are onl

United States - English - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. the morphine sulfate extended-release tablets 100 and 200 mg tablet strengths are high dose, extended-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release tablets are

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. the morphine sulfate extended-release tablets 100 and 200 mg tablet strengths are high dose, extended-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release tablets are

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. the morphine sulfate extended-release tablets 100 and 200 mg strengths are a high dose, extended-release, oral morphine formulation indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release tablets are only i

United States - English - NLM (National Library of Medicine)

meridian medical technologies, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg in 0.7 ml - morphine sulfate injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve morphine sulfate injection for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia morphine sulfate injection is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - concurrent use of monoamine oxidase inhibitors (maois) or use of maois within the last 14 days [see warnings and pr

United States - English - NLM (National Library of Medicine)

hospira, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 50 mg in 1 ml - morphine sulfate is indicated for the relief of severe pain. it is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. it is likewise effective in the control of post-operative pain. the use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. tolerance develops to the analgesic effects and increasingly higher dose